Issue #4: Cannabis BioScience Holdings, CHNC
Cannabis BioScience Holdings, Ticker Symbol: CHNC, was brought to our attention through the extremely robust DD pack put together by @jeff_lien, @mikulscarn, @bigfundamentalz, @wildrhino.
The content contained within are the highlights from their DD pack. The full DD pack is linked above.
Authors Note:
The team compiling this DD pack does not have affiliation to CHNC, but sent the first draft to the CHNC team and received a FAST response saying they would be happy to look it over.
All factual information in this DD pack has been reviewed by the company and is verifiably accurate to the best of their knowledge.
Follow CHNC on Twitter! CHNC @ChnCstock
EXECUTIVE SUMMARY:
China Infrastructure Corp -> Cannabis BioScience Holdings. Name change approved!
Employees are rewarded with stock, resulting in 66% insider ownership today as the company begins rolling out new products/services.
As of 2020, the company’s past filings have been cleaned up and debt has been ELIMINATED!
DISRUPTORS! CHNC values education above all and strives to change the medical marijuana industry, not just be part of it. They aim to expedite acceptance by providing quality sources of information and guiding the world towards building sensible infrastructure that allows marijuana to be used in therapeutic scenarios WORLDWIDE!
All the resources to become a Contract Research Organization in the medical marijuana industry… and conduct their own trials!
In fact, CHNC is already conducting their own trials on cancer and respiratory diseases!
Covers everything you could imagine in the medical marijuana space: clinical research, publications, education, consultation, franchising… more to be revealed.
Facts:
PINK CURRENT
No toxic notes or dilution
No reverse split
Executed a 4B share buyback earlier this year
Float is 1.68 billion.
Precision Research Institute, LLC (PRI) is a medical research center that allows
@ChnCstock to perform clinical trials.
@pri_center has contracts with:
Abbvie
Samumed
Gilead
Intercept
Shire Pharmaceuticals
To assist in becoming a leader in cannabis clinical trials & education,
@ChnCstock acquired Pharmacology University Inc.
@PharmacologyU offers consulting services to doctors, dispensary owners, & growers in:
US
Puerto Rico
Latin & South America
@PharmacologyU also offers:
Digital magazine on medical cannabis: Cannabis World Journals – The best Magazine of Medical Cannabis
Clinical trials: Medical Studies | ALPHA Research Institute, LLC | United States
Medical cannabis online academy: Alpha Academy of Science: Academia sobre salud y ciencia
Online cannabis courses: English - Home
Late 2020, @ChnCstock utilized their acquisitions, @pri_center & @PharmacologyU, to study the effects of cannabis extracts and the three stages of COVID-19:
Inflammation
Immunosuppression
Catabolism Syndrome
In 2021, @ChnCstock launched ALPHA Fertility & Sleep Center, a company focusing on curing chronic sleep-related disorders & fertility problems.
@alpha_fsc provides the following services:
Fertility Consultations
Sleep Studies
Wellness Programs
In 2021, @ChnCstock reaffirmed that their focus is not only on cannabis, but also clinical studies in:
Knee osteoarthritis
Streptococcus & Syncytial virus vaccine
Asthma
Chlamydia & Gonorrhea
COVID-19
On June 24, 2021, @ChnCstock changed its name to Cannabis Bioscience International Holdings, Inc.
This change reflected their line of business and where they operated:
Europe
Latin America
Middle East
USA
Catalysts
PRI's phase II & III clinical trials.
Update on PRI's contracts.
Update on cannabis treatment of COVID.
Update on osteoarthritis clinical trials.
Update on Streptococcus & Syncytial vaccine.
FINRA name & ticker change.
WHAT IS CHNC?
Simply put, CHNC’s focus is to advance research and understanding of treatment options (mainly for medical marijuana) with the goal of providing solutions to “people who need it most”.
They want to be the change they wish to see in the world and destigmatize the cannabis industry.
A look at CHNC’s landing page for their new website highlights their “core values. They are passionate about making a difference in a budding industry!
CHNC SHAREHOLDER FACTS
PINK CURRENT OTC Markets | CHNC | Overview | OTC Markets
Increased revenue by 285% in 2020 calendar year
Issued a 4B share buyback to occur over 2 years – recently completed the final transaction!
Float is 1.68B!
8B OS, with 6B being restricted!
66% insider ownership (financials on front page of website!)
No toxic debt or dilution
No reverse split
UPCOMING CATALYSTS
FINRA NAME & TICKER CHANGE! Reflects expanding international activities and new company focus after being revived in recent years.
Much more fitting for a new company vision: CHNC Announces Name Change to Cannabis Bioscience International Holdings, Inc.
Company will provide fully audited financials for the name change, they are due EARLY SEPTEMBER!
Ongoing and future clinical trials (phase II & III at least)
Can expect updates on this relatively soon… multiple trials set to conclude in September!
Revenue is growing as more products are offered and the company vision expands
Update on cannabis treatment of COVID: CHNC Publishes Its Phytotherapy Project With Cannabinoids That Seeks to Attack the Effects of COVID-19
Update on streptococcus and syncytial vaccines
HOW WILL CHNC SUCCEED?
CHNC is a research and development, pharma, education, clinical testing, and multinational organization working to set the standards for a growing industry in 109 countries.
CHNC owns Pharmacology University. They have 150+ publications, soon to be available on Amazon, Walmart, Google Play, Barnes and Noble, Audible, and more platforms.
The accounts are currently open and finishing transfer to E-format. The content is available in FIVE different languages, that include English, Spanish, Portuguese, Italian, and Arabic.
In 2022, Pharmacology University plans to start production in Hindu, Mandarin, French, and German. This is a HUGE revenue stream.
COVID-19 Therapeutic Treatment, Letter of Introduction
Excerpt, the full LOI linked above
"Our project’s primary function will challenge the testing, efficacy and safety of the phytotherapy, in addition to prove our empirical dose range, through a series of clinical studies. Our strategical plan is to conduct Phase I - Phase III Clinical Trials, with the initiation of our NDA Application and Protocols.Phase I will consist of a group of 85 subjects, primarily testing the safety of our treatment. Phase II will consist of 225 subjects, testing the safety and efficacy of the treatment. Additionally, Phase III will consist of 400 subjects, focusing on the efficacy of the treatment with safety always being primary. At the completion of these clinical trials, the next objective is to start the manufacturing and international distribution of the treatment."
ALPHA RESEARCH INSTITUTE
COVID-19, cancer, cannabis, education, retail, city and government, clinical trials, sleep, fertility
ARI Instagram Photos and Videos
ALPHA SLEEP CENTER
This is a fully operating sleep and fertility clinic with a TON of services and a REVENUE generator!
PHARMACOLOGY UNIVERSITY
Link to Pharmacology University
ALPHA ACADEMY OF SCIENCE
Link to Alpha Academy of Science
CHNC Publishes Its Phytotherapy Project With Cannabinoids That Seeks to Attack the Effects of COVID-19
“Houston, Texas--(Newsfile Corp. - November 18, 2020) - CHNC (OTC Pink: CHNC) Phytotherapy therapeutic program, comprised of cannabinoid molecule formulations, has the advantage of not having adverse effects and was developed to treat each of the three stages of COVID-19; from moderate, to the critical curse, and for the final leg of persistent inflammation, immunosuppression and catabolism syndrome.”
THE TEAM
Industry professionals, cannabis advocates, general counsel, and research doctors
Dante Picazzo owns 58.5% of all stock. Dilution and Reverse Splits are off the table.
Digital magazine on medical cannabis
Cannabis World Journals – The best Magazine of Medical Cannabis
